Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Trelegy

- PMLiVE

GlaxoSmithKline agrees $2.2bn dementia mAb deal with Alector

The focus of the deal is two clinical-stage monoclonal antibodies in development for a number of neurodegenerative diseases

- PMLiVE

Elliott Management puts pressure on GSK after years of ‘disappointing performance’

Hedge fund has published a 17-page letter outlining recommendations following GSK's investor day last week

- PMLiVE

CHMP recommends eight new medicines for EU approval

BMS’ CAR T therapy Abecma and BioMarin’s dwarfism drug Voxzogo among positive recommendations

- PMLiVE

GSK aims for £33bn in sales by 2031 as CEO Walmsley lays out ten-year strategy

'New' GSK will build on growth potential of its vaccines and speciality medicines portfolios

- PMLiVE

GSK partners with iTeos Therapeutics on next-gen immuno-oncology drug

British drug-maker will pay $625m upfront for access to iTeos' anti-TIGIT monoclonal antibody

- PMLiVE

GSK, Vir’s COVID-19 mAb scores FDA emergency use approval

Interim phase 3 trial results found sotrovimab reduced the risk of hospitalisation or death by 85% compared to placebo

- PMLiVE

Sanofi, GSK begin enrolment for phase 3 COVID-19 vaccine study

Study will investigate two formulations targeting the Wuhan strain and the South African variant

- PMLiVE

UK government ‘concerned’ over Elliott Management’s plans for GSK

'Activist' hedge fund Elliott Management has built up a sizeable stake in the British drugmaker

- PMLiVE

GSK and Medicago’s COVID-19 vaccine shows promising antibody responses in phase 2

Neutralising antibody responses in vaccinated participants were about ten times higher than those seen in a panel of sera from recovering COVID-19 patients

- PMLiVE

Sanofi, GSK’s COVID-19 vaccine generates strong immune responses across all age groups

Sanofi/GSK delayed their COVID-19 vaccine programme in December 2020 after the vaccine candidate induced low immune responses in older adults

- PMLiVE

Positive results for GSK/CureVac’s COVID-19 vaccine

Vaccine candidate generated strong immune responses in preclinical testing

- PMLiVE

EMA introduces new measures to enable flexibility for non-COVID-19 procedures

Regulator will streamline processes to allow its experts to focus on COVID-19-related assessments

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links